EnquBio, a San Diego-based R&D technology and service company, is excited to announce the formal start of its operation alongside the launch of its Preclinical Drug Discovery Services. This milestone marks a significant step forward in EnquBio's commitment to advancing healthcare through innovative solutions and dedicated supports.

With a focus on improving the drug discovery process, EnquBio offers a comprehensive suite of services tailored to meet the evolving needs of pharmaceutical and biotechnology companies worldwide. Leveraging cutting-edge technologies and a multidisciplinary approach, EnquBio aims to accelerate the development of novel therapeutics with reliable, high-quality data, quick and dependable timelines, and competitive pricing.

​

"We are thrilled to officially open our doors and introduce our preclinical drug discovery services to the scientific community," remarked Dr. Tan, CEO of EnquBio. "At EnquBio, we are driven by a passion for innovation and a dedication to making a tangible difference in drug discovery. With our state-of-the-art facilities and a team of seasoned experts, we are poised to redefine the landscape of drug discovery technology development and R&D Services." EnquBio's preclinical drug discovery services encompass a spectrum of offerings, including exploratory biology, HTS and SAR screening, in vitro and in vivo pharmacology, biomarker discovery, clinical sample tests and more. 

​

"Our mission is to empower our clients with the tools and insights necessary to navigate the complexities of drug discovery efficiently," added Dr. Tan. "Through collaborative partnerships and a relentless pursuit of excellence, we strive to unlock new therapeutic opportunities and drive meaningful progress in healthcare."

​

EnquBio invites partners and collaborators to join us in shaping the landscape the drug R&D and services. With a unwavering focus on innovation, integrity, and impact, EnquBio is ready to spark breakthroughs that will change healthcare for the better, both now and in the future.

We at Enqubio, a burgeoning biotechnology company, are pleased to announce that we have completed our Series A fundraising from a group of private investors. This marks a significant step in our journey towards contributing to the pharm/biotech sector. The company has been fortunate to attract the support of investors who share our vision for innovation in drug R&D and practical solutions that aim the needs of industry.

"With our eyes set on opening our doors in Q1 2024, this funding round represents more than just financial support; it embodies faith in our modest vision and our approach to the industry," said Dr. Xuehai Tan, co-founder and managing director of EnquBio, Inc. "We are grateful of our investors' belief in us and are enthusiastic about the journey ahead."

Our upcoming facility, once opened, will be a modest yet fully-equipped space for research & development around new hit/lead discovery platform, SAR for lead identification that contains in vitro, in vivo, ex vivo capabilities.

We invite you to stay connected for further updates on our progress and contact us for any interests around our business